Skip to main content

Table 1 Demographic information for the sample

From: Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease

 

N

ADAD Mutation Groups

NCs vs. All MCs

NCs

(179)

Asymptomatic MCs

(183)

Symptomatic MCs

(74)

η²

p-value1

Age

436

   

0.000

0.79

Mean (SD)

 

37.5 (10.6)

34.3 (9.1)

46.3 (8.7)

  

Sex

436

    

0.75

Female

 

101 (56%)

104 (57%)

37 (50%)

  

Male

 

78 (44%)

79 (43%)

37 (50%)

  

Education

436

   

0.007

0.030

Mean (SD)

 

15.0 (2.8)

14.8 (2.7)

13.7 (3.1)

  

Self-Selected Race

436

    

0.69

Aboriginal Australian or Torres Strait Islander*

 

< 5

< 5

< 5

  

American Indian or Alaska Native*

 

< 5

< 5

< 5

  

Asian*

 

5 (2.8%)

< 5

< 5

  

Black or African American*

 

< 5

< 5

< 5

  

Hispanic or Latinx*

 

< 5

< 5

< 5

  

Middle Eastern or North African*

 

< 5

< 5

< 5

  

Native Hawaiian or Other Pacific Islander*

 

< 5

< 5

< 5

  

White

 

152 (85%)

155 (85%)

64 (86%)

  

More than one race

 

14 (7.8%)

11 (6.0%)

4 (5.4%)

  

Unknown

 

5 (2.8%)

10 (5.5%)

2 (2.7%)

  

CDR

436

    

< 0.001

0

 

179 (100%)

183 (100%)

0 (0%)

  

0.5

 

0 (0%)

0 (0%)

44 (59%)

  

1

 

0 (0%)

0 (0%)

26 (35%)

  

2

 

0 (0%)

0 (0%)

4 (5.4%)

  

EYO

436

   

0.003

0.16

Mean (SD)

 

-11.0 (11.4)

-14.3 (9.0)

1.4 (5.7)

  

APOE

436

    

0.86

ε4-

 

124 (69%)

124 (68%)

52 (70%)

  

ε4+

 

55 (31%)

59 (32%)

22 (30%)

  

Variant

436

    

0.45

APP

 

38 (21%)

38 (21%)

13 (18%)

  

PSEN1 Codon < 200

 

55 (31%)

48 (26%)

23 (31%)

  

PSEN1 Codon 200+

 

65 (36%)

75 (41%)

37 (50%)

  

PSEN2

 

21 (12%)

22 (12%)

1 (1.4%)

  
  1. * Fewer than 5 participants per group selected this race. Specific numbers and percentages for these groups are not reported to prevent unblinding of participant mutation-carrier status
  2. ADAD, Autosomal Dominant Alzheimer Disease; NC, Non-carrier; MC, Mutation-carrier; CDR, Clinical Dementia Rating; EYO, Estimated years until symptom onset; APOE, Apolipoprotein E; APP, Amyloid Precursor Protein; PSEN, Presenilin
  3. 1Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test